2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector [Adbry]
- RxCUI
- 2686065
- RxNorm name
- 2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector [Adbry]
- Display name
- 2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector [Adbry]
- Full name
- 2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector [Adbry]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:23
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761180 | Adbry | tralokinumab-ldrm | 351(a) | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Adbry | TRALOKINUMAB-LDRM | LEO Pharma Inc. | d8020b69-3001-44e2-9b5d-5f93d9aaf6e1 | 2025-12-17 | Warnings, Adverse reactions | 2686065 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| d8020b69-3001-44e2-9b5d-5f93d9aaf6e1 | 2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector [Adbry] | SBD | 15 | These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY ® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 2021 | 20251217 |
| d8020b69-3001-44e2-9b5d-5f93d9aaf6e1 | Adbry 300 MG in 2 ML Auto-Injector | PSN | 15 | These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY ® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 2021 | 20251217 |
| d8020b69-3001-44e2-9b5d-5f93d9aaf6e1 | Adbry 300 MG per 2 ML Auto-Injector | SY | 15 | These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY ® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 2021 | 20251217 |